JP2024519964A5 - - Google Patents
Info
- Publication number
- JP2024519964A5 JP2024519964A5 JP2023572168A JP2023572168A JP2024519964A5 JP 2024519964 A5 JP2024519964 A5 JP 2024519964A5 JP 2023572168 A JP2023572168 A JP 2023572168A JP 2023572168 A JP2023572168 A JP 2023572168A JP 2024519964 A5 JP2024519964 A5 JP 2024519964A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- day
- multispecific protein
- cancer
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191488P | 2021-05-21 | 2021-05-21 | |
| US63/191,488 | 2021-05-21 | ||
| US202163253714P | 2021-10-08 | 2021-10-08 | |
| US63/253,714 | 2021-10-08 | ||
| PCT/US2022/030323 WO2022246244A1 (en) | 2021-05-21 | 2022-05-20 | Dosing regimens for protein therapeutics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024519964A JP2024519964A (ja) | 2024-05-21 |
| JP2024519964A5 true JP2024519964A5 (https=) | 2025-05-27 |
Family
ID=82258425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023572168A Pending JP2024519964A (ja) | 2021-05-21 | 2022-05-20 | タンパク質治療薬のための投薬レジメン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240262920A1 (https=) |
| EP (1) | EP4341291A1 (https=) |
| JP (1) | JP2024519964A (https=) |
| KR (1) | KR20240024819A (https=) |
| AU (1) | AU2022276523A1 (https=) |
| CA (1) | CA3219832A1 (https=) |
| WO (1) | WO2022246244A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024149821A1 (en) * | 2023-01-13 | 2024-07-18 | F. Hoffmann-La Roche Ag | Treatment of cancer using a hla-a2/wt1 x cd3 bispecific antibody and venetoclax/azacitidine |
| WO2025181039A1 (en) * | 2024-03-01 | 2025-09-04 | Molecular Partners Ag | Therapeutic combinations comprising a multi-specific t cell engager |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| JP2008501621A (ja) | 2003-05-31 | 2008-01-24 | マイクロメット アクツィエン ゲゼルシャフト | Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物 |
| MXPA06004035A (es) | 2003-10-16 | 2006-08-31 | Micromet Ag | Aglutinantes cd3 de-inmunizados multi-especificos. |
| US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
| NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
| MX2009010611A (es) | 2007-04-03 | 2010-03-26 | Micromet Ag | Enlazadores biespecificos, especificos para especies. |
| JP2011526792A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＮＦ−αアンタゴニスト多重標的結合性タンパク質 |
| US20110293619A1 (en) | 2008-10-01 | 2011-12-01 | Micromet Ag | CROSS-SPECIES-SPECIFIC PSMAxCD3 BISPECIFIC SINGLE CHAIN ANTIBODY |
| NO2344540T3 (https=) | 2008-10-02 | 2018-04-28 | ||
| CA2785907A1 (en) | 2009-12-29 | 2011-07-28 | Emergent Product Development Seattle, Llc | Ron binding constructs and methods of use thereof |
| US20130129723A1 (en) | 2009-12-29 | 2013-05-23 | Emergent Product Development Seattle, Llc | Heterodimer Binding Proteins and Uses Thereof |
| TWI653333B (zh) | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| AU2011286024B2 (en) | 2010-08-02 | 2014-08-07 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
| KR102060389B1 (ko) | 2011-05-21 | 2019-12-31 | 마크로제닉스, 인크. | 사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자 |
| JP6509724B2 (ja) | 2012-04-20 | 2019-05-08 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Ｃｄ３結合ポリペプチド |
| WO2016094873A2 (en) | 2014-12-12 | 2016-06-16 | Emergent Product Development Seattle, Llc | Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods |
| CN114181309B (zh) | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
| CN109952112B (zh) * | 2016-09-21 | 2024-09-06 | 阿帕特夫研究和发展有限公司 | Cd123结合蛋白和相关的组合物和方法 |
| WO2019050521A1 (en) * | 2017-09-07 | 2019-03-14 | Macrogenics, Inc. | DOSAGE SCHEMES OF BISPECIFIC DIACORPS CD123 X CD3 IN THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES |
| JP2022526640A (ja) * | 2019-04-10 | 2022-05-25 | マクロジェニクス，インコーポレーテッド | 血液悪性腫瘍の治療における二重特異性ｃｄ１２３×ｃｄ３ダイアボディの投薬レジメン |
-
2022
- 2022-05-20 EP EP22734403.3A patent/EP4341291A1/en active Pending
- 2022-05-20 CA CA3219832A patent/CA3219832A1/en active Pending
- 2022-05-20 WO PCT/US2022/030323 patent/WO2022246244A1/en not_active Ceased
- 2022-05-20 JP JP2023572168A patent/JP2024519964A/ja active Pending
- 2022-05-20 KR KR1020237043188A patent/KR20240024819A/ko active Pending
- 2022-05-20 US US18/562,725 patent/US20240262920A1/en active Pending
- 2022-05-20 AU AU2022276523A patent/AU2022276523A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102009238B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| JP2025111463A5 (https=) | ||
| KR101968498B1 (ko) | 암의 치료 및/또는 예방용 의약 조성물 | |
| JP2021510736A5 (https=) | ||
| JP2021514664A5 (https=) | ||
| JP2025000862A5 (https=) | ||
| JP2021524244A5 (https=) | ||
| Zhang et al. | Monoclonal antibodies as therapeutic agents in oncology and antibody gene therapy | |
| JP2024519964A5 (https=) | ||
| JP2022526420A5 (https=) | ||
| JP2025506318A5 (https=) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2021528047A5 (https=) | ||
| JP2023546743A5 (https=) | ||
| JP2025038088A5 (https=) | ||
| IL297619A (en) | Use of a multimeric anti-dr5 binding compound in combination with cancer therapy for the treatment of cancer | |
| JP2022543780A5 (https=) | ||
| EP2683737A1 (en) | Extracellular targeted drug conjugates | |
| US20250270323A1 (en) | Hhla2 binding agents with novel activity | |
| EP4640707A1 (en) | Anti-cmet antibody, antibody-drug conjugate, and preparation method therefor and use thereof | |
| US11648310B2 (en) | Combination of anti-FGFR4-antibody and bile acid sequestrant | |
| JP2024522075A5 (https=) | ||
| JP2024519078A5 (https=) | ||
| JP2024519529A5 (https=) | ||
| WO2023163087A1 (ja) | 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬 |